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Targets of alloantibodies in Alport anti-glomerular basement mem-
brane disease after renal transplantation. A minority of patients with
Alport syndrome develop anti-GBM disease in their allografts after renal
transplantation. Clinically, the renal disease appears indistinguishable
from Goodpasture’s disease of native kidneys, in which the target of
autoantibodies has been identified as the NC1 domain of the a3 chain of
type IV collagen, a3(IV)NC1. However, in the majority of cases, Alport
syndrome is due to mutations in the gene encoding the a5 chain of type IV
collagen, located on the X chromosome. Neither chain is detectable in the
glomerular basement membrane (GBM) of most patients with Alport
syndrome. We investigated the targets of the alloantibodies of 12 Alport
patients who developed post-transplant anti-GBM disease by Western
blotting onto recombinant NC1 domains made in insect cells. Binding to
these antigens, for both typical Goodpasture and Alport anti-GBM
antibodies, was strong and conformation-sensitive. Nine antibodies
showed selective binding to a5(IV)NC1. This specificity was confirmed by
the demonstration of binding to a 26 kDa band of collagenase-solubilized
human GBM, and/or binding to normal epidermal as well as renal
basement membranes by indirect immunofluorescence. One antibody
showed binding to a5 and a3(IV)NC1, while two showed predominant
binding to a3(IV)NC1. All seven patients whose pedigree or mutation
analysis showed X-linked inheritance had predominant anti-a5 reactivity.
One with predominant anti-a3 reactivity had a COL4A3 mutation. These
findings show that human anti-GBM disease can be associated with
antibodies directed towards different molecular targets. a5(IV)NC1 is the
primary target in most patients with X-linked Alport syndrome who
develop post-transplant anti-GBM disease.
In spontaneous anti-glomerular basement membrane disease in
humans (anti-GBM, or Goodpasture’s disease), the major target
of autoantibodies is the NC1 domain of the a3 chain of type IV
collagen [1–3]. The absence of Goodpasture antigen in the
glomerular basement membrane of most patients with Alport
syndrome, and coupled with the observation that anti-GBM
disease sometimes occurs in the renal allografts of patients with
Alport syndrome [4–6], led to the natural assumption that in this
variant of anti-GBM disease the target of autoantibodies was the
same. Several studies have seemed to support this premise, but
some patients’ antisera have shown different properties from
Goodpasture antisera. Most distinctive was the observation that
some Alport anti-GBM sera bind to epidermal basement mem-
brane. Such binding is not seen with Goodpasture sera.
Type IV collagen is a major and essential component of all
basement membranes. Six isoforms, a1 to a6, are encoded by the
genes COL4A1 to COL4A6 [7]. In the GBM type IV collagen is
predominantly composed of a3, a4 and a5 chains. The COL4A5
mutations that most commonly underly Alport syndrome usually
result in the loss of all three of these chains, which are replaced by
the ubiquitous a1 and a2 chains. In the GBM this is ultimately an
inadequate compensation, because there is a progressive loss of
renal function [7]. Progressive sensorineural deafness and the
ocular abnormalities of Alport syndrome can be attributed to a
similar failure of an a5-containing type IV collagen network. The
a5 chain is expressed at other locations, including the alveolar
basement membrane, where the absence of a5, and consequently
of other tissue-specific isoforms, seems to have no deleterious
effect. It is coexpressed with the a6 chain in epidermal basement
membrane, a fact that is diagnostically useful [7]. In a minority of
patients the Alport phenotype may be caused by mutations,
usually recessive, in the COL4A3 and COL4A4 genes on chro-
mosome 2 [8, 9].
After renal transplantation in Alport syndrome the a3, a4 and
a5 chains in the allograft GBM may appear foreign to the new
host’s immune system. Linear deposition of antibody without
disease may be quite common [10, 11], but there are at least 29
examples of anti-GBM disease in the literature. In most cases this
has led to the loss of allograft function. In all cases disease was
limited to the allograft. In some published cases where the target
of alloantibodies has been investigated it has appeared to be
a3(IV)NC1, as in Goodpasture’s disease, while in other reports
the target is clearly distinct from a3(IV)NC1 [12–17]. However,
reagents for specific detection of antibodies to a5(IV)NC1 have
only become available recently, and some of the studies have
relied on antigen made in E. coli, where malfolding may reduce
the sensitivity and specificity of binding.
We reasoned that as the expression of a5(IV) collagen is
deficient or absent in most patients with Alport syndrome, these
patients are less likely to be immunologically tolerant to the a5
chain than to the a3 or a4 chains. The a5 chain in the trans-
planted organ would then appear ’foreign’ to the recipient im-
mune system, and would likely be the most powerful immunogen.
We have made recombinant a5 and a3 chains in insect cells in a
conformation that binds auto- and allo-antibodies strongly, and
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used them to distinguish anti-a5(IV)NC1 reactivity from the
anti-a3(IV)NC1 reactivity typical of Goodpasture’s disease. We
show that alloantibody binding to a5(IV)NC1 is to conforma-
tional epitopes, and that in the patients studied, a5(IV)NC1 was
the dominant target for all of those with X-linked disease.
METHODS
Patients and sera
Antibodies came from patients with Alport syndrome in whom
anti-GBM disease was diagnosed after renal transplantation by
the finding of crescentic glomerulonephritis, with linear IgG
fixation and/or circulating anti-GBM antibodies. They were either
serum samples, frozen in aliquots, or plasma exchange samples,
frozen in aliquots, or in one case antibodies purified on a Protein
A column during therapeutic immunoadsorption. The sera com-
prised all the samples from such patients that were sent to us for
analysis. Histories and family histories were ascertained from the
referring physicians in the case of non-UK samples. Five patients
have been described previously (indicated in Table 1). Control
sera were from patients with well-characterized Goodpasture’s
disease, with or without lung hemorrhage, and from normal
individuals.
Immunohistochemistry
Immunofluorescence studies of snap-frozen normal human skin
were performed as previously described [12]. Skin sections (4
micron) were air-dried and fixed in 95% ethanol at 4°C for five
minutes, followed by three rinses in PBS at room temperature.
The sections were then incubated in 6 M urea, 0.1 M glycine, pH
3.5, for one hour at 4°C. The denatured sections were reacted at
room temperature with normal human serum or patient serum,
followed by FITC-conjugated goat anti-human IgG (Kallestad),
and viewed under an epifluorescence microscope with appropriate
filters. For several samples this analysis had been performed at
other centers and an insufficient sample remained to repeat the
investigation.
Recombinant antigen
Recombinant a3(IV)NC1-bearing collagen minichains were
made in insect cells using the baculovirus expression system as
previously described [20]. cDNAs for a1(IV)NC1 and a5(IV)NC1
were substituted for the a3(IV)NC1 domain in similar constructs,
and recombinant baculovirus prepared in the same way. For the
Western blots described here supernatants of infected cells were
used after partial purification by cation exchange over WP Car-
boxy-Sulfon beads (JT Baker Inc., Phillipsburg, NJ, USA). In
order to make the constructs encoding a1 and a5(IV)NC1, the
following manipulations were performed. The BamHI/HindIII
fragment of the plasmid pHT-21 [21] was subcloned into pGEM,
and amplified with the oligonucleotide primers TTGCCAG-
GATCCATGGGGCCT and TTGGTACCTCGAGGCTTCATTA.
This introduced XhoI and KpnI sites in the 39 non-coding region.
The BamHI/KpnI a1(IV)NC1 cDNA fragment was then used to
replace the a3(IV)NC1 cDNA fragment in the baculovirus trans-
fer vector described above. a5(IV)NC1 cDNAs were amplified
from reverse-transcribed RNA from human renal cortex using the
primers CCATGGATGGTCCCCCT and CTCGAGACACTG-
CATCCTAG, and cloned into pUC12 cut with SmaI. The NcoI/
XhoI fragment was subcloned into the same sites of an
a3(IV)NC1 cDNA into which BamHI and NcoI sites had been
introduced in the collagenous region, and XhoI and KpnI sites into
the 39 non-coding region [20]. The BamHI/KpnI fragments of this
plasmid was then used to replace the a3(IV)NC1 cDNA fragment
in the baculovirus transfer vector in two stages. The sequences of
all PCR products were verified by nucleotide sequencing. RNA
was extracted from fresh or snap-frozen human kidney by the
guanidinium thiocyanate/phenol/chloroform method [22]. Poly-
merase chain reaction (PCR) amplification was performed using
Taq (Perkin Elmer) or Vent (New England Biolabs) polymerases
and 30 cycles of the following pattern in a Perkin Elmer Cetus
thermocycler: 94°C one minute, 55°C one minute, 72°C two
minutes; followed by a final 10 minutes step at 72°C.
Antipeptide antibodies
Synthetic peptides of sequences LATIERSEMFK (a1), LASL-
NPERMFR (a3), and LATVDVSDMFS (a5), corresponding to
residues, 194 to 204 of NC1 domains numbered according to the
sequence of a1(IV), were conjugated to keyhole limpet hemocy-
anin using glutaraldehyde. These were used to immunize rabbits,
and antibody production verified by ELISA using free peptides
[23, 24]. Antisera were used to confirm the production of recom-
binant protein and to ensure comparable loading onto SDS-
PAGE gels.
Table 1. Patient characteristics
Patient
Recombinants EBM
binding Mutation Commentsa1 a3 a5
a 2 2 1 1 COL4A5 deletion Oliver et al 1991 NDT [29]
b 2 2 1 1 X-linked
c 2 (1) 1 1 n.k.
d 2 2 1 1 COL4A5 Patient 197002 from [19]
e 2 2 1 1 COL4A5 deletion Patient MC from [13, 17]
f 2 2 1 1 n.k.
g 2 (1) (1) 2 n.k. a3 and a5 binding approximately equal
h 2 2 1 1 COL4A5 deletion Patient JE from [12, 17]
i 2 2 1 2 COL4A5 deletion
j 2 1 2 2 COL4A3 point mutation The only pure anti-a3 response in this series
k 2 1 1 1 n.k. Described before the underlying diagnosis of
Alport syndrome was appreciated [18]
l 2 2 1 2 n.k.
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Western blotting
Western blotting was performed with partially purified super-
natants of infected Sf9 cells. Samples were run on 10% 8 3 10 cm
SDS-PAGE gels and electroblotted to nitrocellulose membranes
(Schleicher & Schuell) using a wet system, overnight at 30 mA. All
samples were run in non-reducing conditions except for the
denaturation experiments, for which 2% mercaptoethanol was
added to the samples before heating at 95°C for five minutes.
Blotted membranes were blocked with PBS containing 1% Tween
20 and cut into strips. Sera were initially screened for diagnostic
purposes at 1:20, against negative controls (normal individuals) at
1:10, and against positive controls (Goodpasture and Alport
anti-GBM patients). Positive sera were subsequently diluted to
give a clearly visible band comparable to that produced by the
reference Goodpasture serum when used on an a3(IV)NC1-
containing strip at 1:40. This varied from 1:20 to 1:50 (1:200 for
one highly purified protein A preparation). A set of strips
containing each antigen were incubated with each patient’s serum
at the appropriate dilution for one hour, then washed with PBS
0.1% Tween 20 (3 3 2 mins). Each set of strips was then incubated
with an appropriate alkaline phosphatase-conjugated polyclonal
secondary antibody (Sigma Chemical Co., St. Louis, MO, USA)
and washed in the same way. Incubated strips were developed
with nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl phos-
phate [25]. For each patient, the duration of exposure of the strips
to each of the antibodies and to the substrate was the same.
Antibodies from a Goodpasture patient and three Alport
patients were also investigated by pre-incubation with soluble
recombinant antigen containing a3(IV)NC1 or a5(IV)NC1, 10
times the quantity applied to the gel (per strip) for Western
blotting. Recombinant protein suspended in 6 M urea/Tris-HCl,
pH 7.5, was diluted into 1 ml of patients serum at working
concentration, incubated for one hour at 37°C, and then overlaid
onto nitrocellulose strips as described above.
RESULTS
Immunohistochemistry
Eight samples gave positive results in indirect immunofluores-
cence studies on skin (Table 1). Subsequent analysis showed that
positive results were associated with high titers of anti-a5(IV)NC1
reactivity, while negative results were attributable either to the
target molecule not occurring in epidermal basement membrane,
or to the low titer of antibodies in the sample. It was not possible
to distinguish these two possibilities using immunofluorescence
alone.
Recombinant a5(IV)NC1 and a1(IV)NC1 from insect cells
Several recombinant viruses were isolated for each protein, and
supernatants of infected cells were analyzed for production of
recombinant protein by Western blotting using anti-peptide anti-
bodies. It was quickly observed that some Alport anti-GBM sera
bound strongly to recombinant a5(IV)NC1 minichains. Reduc-
tion and denaturation of the recombinant protein abolished
reactivity with patients’ sera (Fig. 1).
Reactivity of Alport anti-glomerular basement membrane sera
The pattern of binding of the patients antibodies to different
antigens is shown in Figure 2 and summarized in Table 1. The
primary target of most Alport anti-GBM sera was a5(IV)NC1.
Interestingly, in the exceptions (patients g, j, and k), in whom
there was primary or equal reactivity with a3, the genetic evidence
showed, or at least raised the possibility (in that the inheritance
was not clear), that the mutation was in the genes encoding the a3
or a4 chain (Table 1). Some additional or cross-reactivity between
different NC1 domains was seen with some Goodpasture or
Alport anti-GBM sera whose primary target appeared to be
another domain. a1(IV)NC1 was least affected by this, although
low levels of binding are seen to the recombinant molecule with
several sera. This has never been accompanied by evidence from
indirect immunohistological studies that a1(IV)-containing base-
ment membranes are recognized by these sera, and our interpre-
tation is that this reflects low avidity cross-reactivity of the
antibodies to molecules of homologous structure and sequence,
seen in these experiments because of the relatively high density of
recombinant antigen presented on the blots. Normal sera (’N’) in
Figure 2 showed no reactivity at normal development times, but
if left longer very faint reactivity with all of the recombinant
molecules could be seen.
Blocking studies (Fig. 3) were perfomed on a Goodpasture
serum (G) and on three Alport anti-GBM antisera (patients a, b
and k) for which sufficient quantities were available. In each case,
specificity was shown by the fact that binding to a recombinant
minichain could be inhibited by the same recombinant molecule
(a3- or a5-bearing), but not by the other. Patient k, who showed
equal reactivity with a3 and a5(IV)NC1, shows blocking of a5
reactivity by a5(IV)NC1 but not by a3(IV)NC1, and of a3
reactivity by a3(IV)NC1 but not by a5(IV)NC1. Interestingly, the
a1 reactivity of patient a was blocked by recombinant a5(IV)NC1
but not by a3(IV)NC1, supporting the assertion that this interac-
tion is caused by low avidity cross-reactivity.
DISCUSSION
Different patterns of reactivity of Alport anti-GBM sera have
been confirmed by several observers. The studies presented here
show that the usual explanation for this is that the primary
reactivity of most of these antibodies is towards a5(IV)NC1, in
contrast to the predominant anti-a3(IV)NC1 reactivity seen in
Goodpasture’s disease. Like Goodpasture autoantibodies, these
anti-a5(IV)NC1 antibodies bind to conformational epitopes.
Whether there is any further similarity in their epitope specificity
cannot be surmized from this work. It might be predicted that this
should not be the case, as autoimmunity presumably depends on
some specific and limited breakdown in self-tolerance, whereas
here we are observing the response to a molecule that is perceived
as foreign by the recipient immune system.
The a3 and a4 of type IV collagen chains are probably still
produced normally in most patients with Alport syndrome, even
when they are not found in basement membranes [26], although in
a dog model of Alport syndrome mRNA for the tissue-specific
chains appears to be diminished [27]. Indeed, the increased
breakdown of unincorporated chains may increase the exposure
of the immune system to these chains. There is some evidence that
patients with a complete COL4A5 deletion are more likely to
develop post-transplant anti-GBM disease than others with point
mutations or other causes of Alport syndrome [7, 17]. These obser-
vations and our results are in keeping with the hypothesis that
patients are most likely to develop alloantibodies to antigens that
are completely absent from their own repertoire. Patients with
X-linked disease generally develop anti-a5(IV) alloantibodies;
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patients who have autosomal recessive disease are more likely to
develop anti-a3 alloantibodies. One case of a COL4A5 mutation
associated with anti-a3 antibodies has been published [28]. In this
example binding of antibodies to bovine a3 and/or a5, and to
recombinant human a3(IV)NC1 (produced in bacteria), was
demonstrated.
It has been hypothesized that there is something unique about
the nephritogenicity of the Goodpasture antigen. Alport post-
transplant anti-GBM disease shows that immunity to the similar
and co-located a5 chain can induce almost indistinguishable
pathology. This indicates that uniqueness for the Goodpasture
antigen lies in its ability to break self-tolerance, not in its location,
accessibility, or other features leading to a highly destructive,
immune-mediated renal disease.
Awareness of this complication of transplantation in Alport
syndrome seems to be increasing, but it is important to point out
that standard anti-GBM assays are not a reliable way of excluding
the diagnosis. We have observed that many of the samples we
have received, even from patients with florid disease, have given
negative or only weakly positive results in immunoassays for
anti-GBM antibodies. This is not surprising, as these assays have
Fig. 1. Binding of autoantibodies to a3(IV)NC1, and alloantibodies to a5(IV)NC1, are conformation-dependent. Western blots of binding to
recombinant minichains with a3 or a5(IV) NC1 components are shown. Binding of two Goodpasture sera (G1, G2) and two Alport post-transplant
anti-GBM sera (A1, from patient c, and A2, from patient d) are shown. For each serum, binding to the 41 kDa band of recombinant minichains is shown;
3 and 3R indicate binding to a3(IV)NC1-containing minichains without and with addition of reducing agent, 5 and 5R indicate the same for
a5(IV)NC1-containing minichains.
Fig. 2. Western blots showing binding of Alport post-transplant anti-
GBM alloantibodies to recombinant collagen minichain (41 kDa) con-
taining a1, a3, and a5(IV)NC1. Patients are labeled a to l. Binding of a
Goodpasture serum, G, and normal serum, N, are also shown. The a5(IV)
binding appears as two bands because it is produced as two isoforms of
slightly differing molecular size, both of which bind antibodies well.
Loading was adjusted to match a single band using anti-peptide antibod-
ies.
Fig. 3. Blocking experiments confirm specificity of anti-a5(IV)NC1 and
anti-a3(IV)NC1 antibodies. Binding to immunoblot strips bearing
minichains of the indicated composition (top) is shown for four patients
(as in Table 1). The lower caption indicates the recombinant protein with
which the patient’s serum was pre-incubated.
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been optimized for detection of anti-a3(IV)NC1 antibodies, and
in some cases the ligand is a purified GBM preparation from
which a5(IV)NC1 may have been depleted. At present renal
biopsy evidence of glomerulonephritis is the only reliable way to
diagnose the disease, and for maximum sensitivity, it must in our
experience be combined with examination by direct immunofluo-
rescence.
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